glp 1 approved for How Employers Can Optimize Benefits in the Era of GLP-1s Decoding GLP-1 Weight Loss Medications
Description
Studies have found that about 5.6% of multi-dose medication vials, like semaglutide, develop bacterial growth over time

The absolute risk increase is approximately 25 additional events per 10,000 person-years

Tirzepatide is Mounjaro at various doses

Am J Gastroenterol 2008
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
Given that many marketed GLP-1 agonists have long half-lives, this can significantly impact the absorption of co-administered drug products

Published research shows 19.1% average weight loss at 12 months
